Rioux F, St-Pierre M, Harvey N, Moisan S, Burhop K E, Drapeau G
Centre de recherche (Université Laval), Hôtel-Dieu de Québec, QC, Canada.
Can J Physiol Pharmacol. 1998 Oct-Nov;76(10-11):983-8. doi: 10.1139/cjpp-76-10-11-983.
Impaired nitric oxide (NO) activity is associated with an increase in blood pressure in rats. Voltage-regulated calcium channels are believed to participate in this hemodynamic event. To further test this hypothesis, we examined the effect of nimodipine and verapamil (calcium antagonists) on the pressor activity of diaspirin-crosslinked hemoglobin (DCLHb), a well-known NO scavenger, in anesthetized rats. Nimodipine, the most potent of the two calcium antagonists used, was also tested against phenylephrine (alpha1-adrenoceptor agonist). The pressor effect of DCLHb was reduced markedly by nimodipine and verapamil, whereas that elicited by phenylephrine, particularly the tonic phase of its pressor response, was resistant to blockade by nimodipine. The bradycardia and tachycardia associated with the pressor effects of DCLHb and phenylephrine, respectively, were not affected by nimodipine. The pressor effect elicited by DCLHb and its alteration by nimodipine were also examined in rats pretreated with 100% O2. This treatment was found to potentiate the pressor effect of DCLHb. However, this synergism did not impair the inhibitory action of nimodipine towards the pressor activity of DCLHb. Altogether these results suggest that the pressor activity of DCLHb in our animal model might involve the participation of voltage-regulated calcium channels.
一氧化氮(NO)活性受损与大鼠血压升高有关。电压门控性钙通道被认为参与了这一血流动力学事件。为了进一步验证这一假说,我们在麻醉大鼠中研究了尼莫地平和维拉帕米(钙拮抗剂)对双阿司匹林交联血红蛋白(DCLHb,一种著名的NO清除剂)升压活性的影响。尼莫地平是所用两种钙拮抗剂中作用最强的,还对其与去氧肾上腺素(α1肾上腺素能受体激动剂)进行了比较测试。尼莫地平和维拉帕米可显著降低DCLHb的升压作用,而去氧肾上腺素引起的升压作用,尤其是其升压反应的强直相,对尼莫地平的阻断具有抗性。分别与DCLHb和去氧肾上腺素升压作用相关的心动过缓和心动过速不受尼莫地平影响。我们还在给予100%氧气预处理的大鼠中研究了DCLHb引起的升压作用及其被尼莫地平的改变情况。发现这种处理可增强DCLHb的升压作用。然而,这种协同作用并未削弱尼莫地平对DCLHb升压活性的抑制作用。总之,这些结果表明在我们的动物模型中,DCLHb的升压活性可能涉及电压门控性钙通道的参与。